Small Molecule Cancer Drugs Market Overview 2021 - Global Size Estimation, Analytical Method, Share, Analysis, Advance Technique, Top 10 Leading Market Leaders and key Trends by 2027
SummaryInterference caused by genetic changes leads to uncontrollable cell growth, resulting in a mass formation, called tumor. The tumor, having to potential of spreading in entire body, is a malignant type.
- Author Company: Coherent Market Insights
- Author Name: Nirav
- Author Email: firstname.lastname@example.org
- Author Website: https://www.coherentmarketinsights.com/
Cancer is a chronic disease leading to abnormal growth in the cells. Interference caused by genetic changes leads to uncontrollable cell growth, resulting in a mass formation, called tumor. The tumor, having to potential of spreading in entire body, is a malignant type. Majority cancers cause owing to the genetic mutation, induced by lifestyle or environmental factors, it can even be hereditary. Cancers are divided in four categories based on its origin – 1) Sarcoma (starts within the connective tissues), 2) Carcinoma (begins within tissues or skin), 3) Leukemia (originating in blood), 4) Lymphoma (begins within the lymphatic system).
Regulatory bodies increasingly approving drugs for small molecule cancer are expected to accelerate growth of the global small molecule cancer drugs market during the forecast period. For instance, Novartis AG, in May 2019, U.S. received approval from the U.S. Food & Drug Administration (FDA) for a combination drug, consisting Piqray and fluvestrant. This drug is first one ever, which specifically treats advanced breast cancer that is HR/HER2-, PIK3CA mutated.
Get Full PDF Sample Copy of Report (AVAIL UP-TO 30% OFF) @
Furthermore, Janssen Pharmaceutical Company, in April 2019, received approval from U.S. FDA for the drug Balversa (erdafitinib), which is indicated to treat locally advanced, FGFR2 or FGFR3 mutated, urothelial carcinoma. The study was an open-label, multicenter, single-arm trial, comprising of 87 participants having urothelial carcinoma which is metastatic or locally advanced along with having developed on or after at least one previous chemotherapy.
Moreover, major players are laying emphasis on strategies for growth such as acquisitions and mergers, collaborations, for achieving competitive edge within the market. For instance, a pharmaceutical company - Pfizer Inc., in June 2019, acquired a drug developing company - Array Biopharma, to expand their product portfolio. Array Biopharma’s product portfolio includes skin cancer treatment drugs and final-stage colorectal cancer treatment drug combination (Braftovi and Mektovi). Factors of such kind are expected to propel growth of the global small molecule cancer drugs market.
North America is expected to gain the highest share in the global small molecule cancer drugs market, due to other organizations associated with cancer drugs taking various initiatives. For instance, American Cancer Society collaborated with Ovarian Cancer Research Alliance, in June 2019, for funding prevention, detection and treatment related research activities for ovarian cancer. Their goal is to collect funds activities of research, to provide support for drug investigation of ovarian cancer. Therefore, initiatives of such kind may positively influence the growth of global small molecule cancer drugs market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy This Complete A Business Report:
Key players functioning in the small molecule cancer drugs market are, Otsuka Pharmaceutical Co. Ltd, Janssen Research and Development LLC, Eli Lilly and Co, Novartis AG, SANOFI AVENTIS US LLC, Pfizer Inc., Baxter Healthcare Corp., HQ Specialty Pharma Corp, Emcure Pharmaceuticals Ltd., and AstraZeneca, Kyowa Kirin Inc.
Global Small Molecule Cancer Drugs - Market Taxonomy
The global small molecule cancer drugs market is divided based on drug class, administration route, distribution channel, as well as regions.
On the basis of Drug Class
- Alkylating Agents
- Antitumor Antibiotics
- Plant Alkaloids
- Topoisomerase Inhibitors
On the basis of Route of Administration
On the basis of Distribution Channel
- Online pharmacies
- Retail pharmacies
- Hospital pharmacies
On the basis of Region
- North America
- Latin America
- Asia Pacific
- Middle East
Get Sample PDF Brochure with Impact of COVID19:
Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Note – In order to provide more accurate Market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.
(*If you have any special requirements, please let us know and we will offer you the report as you want.)
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Senior Client Partner – Business Development